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OBJECTIVE—To determine to what extent plasma C-reactive
protein (CRP) values inﬂuence 5-year all-cause and cardiovascu-
lar mortality in type 2 diabetic individuals, independently of
albumin excretion rate (AER) and other cardiovascular risk
factors, and its incremental usefulness for predicting individual
risk of mortality.
RESEARCH DESIGN AND METHODS—Measurements of
CRP were performed in 2,381 of 3,249 (73.3%) subjects as part of
the population-based Casale Monferrato Study. Its association
with 5-year all-cause and cardiovascular mortality was assessed
with multivariate Cox proportional hazards modeling. The C
statistic and measures of calibration and global ﬁt were also
assessed.
RESULTS—Results are based on 496 deaths in 11.717 person-
years of observations (median follow-up 5.4 years). With respect
to subjects with CRP 3 mg/l, those with higher values had an
adjusted hazard ratio (HR) of 1.51 (95% CI 1.18–1.92) for all-
cause mortality and 1.44 (0.99–2.08) for cardiovascular mortality.
In normoalbuminuric subjects, respective HRs of CRP were 1.56
(1.13–2.15) and 1.65 (1.00–2.74), AER being neither a modiﬁer
nor a confounder of CRP association. In analysis limited to
diabetic subjects without cardiovascular disease (CVD), adjusted
HRs were 1.67 (1.24–2.24) for all-cause mortality and 1.36
(0.83–2.24) for cardiovascular mortality. The improvement in
individual risk assessment was marginal when measured with
various statistical measures of model discrimination, calibration,
and global ﬁt.
CONCLUSIONS—CRP measurement is independently associ-
ated with short-term mortality risk in type 2 diabetic individuals,
even in normoalbuminuric subjects and in those without a
previous diagnosis of CVD. Its clinical usefulness in individual
assessment of 5-year risk of mortality, however, is limited.
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nﬂammation is a crucial factor in the atherosclerotic
disease process (1). High-sensitivity C-reactive protein
(CRP) is an acute-phase response protein that is con-
sidered both a marker of inﬂammation and a predictor
of cardiovascular events, including myocardial infarction,
stroke, peripheral arterial disease, and sudden cardiac death
(2–4). CRP may also act directly on atherosclerosis, promot-
ing endothelial cell activation and adhesion molecule expres-
sion, resulting in endothelial dysfunction (5,6).
Studies have pointed out that diabetic individuals have
higher concentrations of CRP than nondiabetic individu-
als, suggesting an increased role of inﬂammation in the
accelerated atherosclerosis seen in these patients (7–14).
As CRP has been reported to correlate with cardiovascular
risk factors, such as hyperglycemia, hypertension, and
lipids, its predictive role on cardiovascular events in
individuals with type 2 diabetes could be merely due to the
effect of associated factors (7–9). Population-based stud-
ies examining the association between CRP and cardio-
vascular disease in diabetic people are limited (4,10). Most
studies have been hampered by 1) the recruitment of
clinic-based rather than population-based cohorts of sub-
jects, which limits the extrapolation of results to the whole
diabetic population (2,11); 2) the cross-sectional rather
than prospective study design, which limits the identiﬁca-
tion of temporal relationship between CRP and events
(7–9,12–14); and 3) the spectrum of risk factors assessed
simultaneously, not including microalbuminuria, the main
predictor of cardiovascular events in diabetic people, thus
limiting the assessment of the interrelationship between
markers of inﬂammation and markers of endothelial dys-
function (4,10). Moreover, conﬂicting results on the incre-
mental usefulness of CRP measurement for cardiovascular
prediction have been provided in nondiabetic subjects
(15–18), whereas no data are available in subjects with
type 2 diabetes.
The aims of this report of the ongoing population-based
Casale Monferrato Study (19–21) were to determine 1)t o
what extent a CRP value inﬂuences 5-year all-cause and
cardiovascular mortality in type 2 diabetic subjects, inde-
pendently of other cardiovascular risk factors; 2) whether
microalbuminuria acts as a confounder or modiﬁer of this
association; and 3) the incremental mortality prediction
using CRP in subjects with type 2 diabetes.
RESEARCH DESIGN AND METHODS
The study base was composed of 3,249 patients with known type 2 diabetes
who in 2000 were residents of the town of Casale Monferrato in northwestern
Italy (93,477 inhabitants) (19). They were identiﬁed in the second prevalence
survey of the Casale Monferrato Study, using independent data sources
(diabetes clinics; administrative data sources), obtaining a high degree of
ascertainment (80%). The study was approved by the institutional review
committee. As described in detail elsewhere, at baseline all patients were
interviewed and examined by trained investigators after having provided
informed consent (19). All laboratory determinations were centralized. Ve-
nous blood samples were collected after overnight fasting for determination
of triglycerides, total cholesterol, HDL cholesterol (enzymatic colorimetric
method after precipitation with Mn
2), apolipoprotein (apo) A1, apoB (turbi-
dimetric method, BM/Hitachi 717; BBR, Tokyo, Japan), and A1C (high-
performance liquid chromatography; Daiichi, Menarini, Japan) (laboratory
reference range 3.8–5.5%). LDL cholesterol was calculated from Friedewald’s
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926 DIABETES, VOL. 58, APRIL 2009formula for all subjects in the cohort whose triglyceride values were 4.48
mmol/l. One overnight timed urine collection was obtained, after exclusion of
urinary tract infection, congestive heart failure, and other known causes of
nondiabetic renal disease, and the urinary albumin concentration was mea-
sured by using the nephelometric method (coefﬁcient of variation [CV]  4%)
(Behring Nephelometer Analyzer; Behring Institute, Marburg, Germany). The
albumin excretion rate (AER) was then calculated. Fibrinogen levels were
measured in 1,399 of 2,381 subjects also having CRP measurements (59%).
High-sensitivity CRP levels were measured using an immunoturbidimetric
method (CV  0.5%) (Roche Diagnostic). Hypertension was deﬁned as systolic
blood pressure 140 mmHg and/or diastolic blood pressure 90 mmHg or
treatment with antihypertension drugs. Central obesity was deﬁned as waist
circumference 102 cm in men and 88 cm in women. Cardiovascular
disease (CVD) was deﬁned as physician-diagnosed myocardial infarction,
angina, coronary artery bypass graft, stroke, arterial disease of lower-limb, or
epiaortic arterial trunks. The Rose questionnaire was also admistered. Coro-
nary heart disease was also deﬁned on the basis of electrocardiographic
abnormalities according to the Minnesota code, as probable (major Q and QS
items, codes 1.1 and 1.2) or possible (minor Q and QS items, S-T/T items,
codes 1.3, 4.1–4.4, and 5.1–5.3). Smoking habit was classiﬁed into one of three
categories (never smoker, ex-smoker if patient stopped smoking at least 1
month before the visit, and smoker). We estimated glomerular ﬁltration rate
(GFR) by using the four-component abbreviated equation from the Modiﬁca-
tion of Diet in Renal Disease Study (all patients were Euripids): estimated
GFR  186  (serum creatinine [mg/dl])
1.154  age
0.203 ( 0.742 if female) (22).
For all patients enrolled the date of diagnosis was retrieved and recorded.
Statistical analysis. Analyses were performed using baseline variables.
Variables distributed normally are presented as means  SD, whereas
variables with skewed distribution were analyzed after logarithmic transfor-
mation (triglycerides, AER, creatinine, and CRP) and results presented as
geometric means and 95% CIs. Differences in clinical characteristics of
patients were assessed using the t test for continuous variables and 
2 test for
ordinal variables. Pearson correlations between CRP and continuous vari-
ables were also performed. ANCOVA was performed to adjust CRP values for
potential confounders. Information as to which subjects had died up to 31
December 2006 was obtained from the demographical ﬁles of towns of
residence, hospital discharges, and autopsy records. Underlying causes of
death were derived and coded by two authors (G.B. and O.S.), according to the
ICD-9. Mortality rates were calculated by dividing the number of deaths
occurring during the study period by the number of person-years of observa-
tion. We performed mortality analyses of the cohort using multivariate Cox
proportional hazards modeling to estimate the hazard ratios (HRs) of cardio-
vascular and all-cause mortality by CRP values, independently of AER and
other risk factors commonly examined in diabetological clinical practice in
Italy (23,24). Results are reported as HRs with 95% CIs for tertiles 2 and 3 of
CRP values compared with tertile 1. Models for either logCRP as a continuous
measure, assessing the multiplicative increase of each increment of CRP to
mortality risk, or clinically relevant cutoff points of CRP (1.0, 1–3, or 3
mg/l) were also constructed. As HRs of CRP values 1–3 mg/l and 1 mg/l were
similar, they were aggregated as the reference category and compared with
CRP values 3 mg/l.
To assess the incremental usefulness of CRP with respect to traditional
cardiovascular risk factors, all models were adjusted for age, sex, diabetes
duration (model 1), hypertension, A1C, smoking, LDL cholesterol, HDL
cholesterol, CVD, and diabetes treatment (model 2). Central obesity (yes
versus no) and treatment with statins (yes versus no) were also included in
models 2 and 3, as they might provide residual confounding of the relationship
between CRP and mortality. The role of AER was examined in model 3 using
clinically relevant strata (20 vs. 20 g/min). Models were constructed with
variables as continuous measures to provide maximum power for detecting an
association between CRP and mortality. In addition, we allowed any of the
following variables to enter the model if they add signiﬁcantly or modiﬁed HRs
of CRP (uric acid, apoA1/apoB, and estimated GFR). The interrelationship
between CRP and ﬁbrinogen with respect to mortality was further assessed
including a categorical variable with two strata of ﬁbrinogen with cutoff point
deﬁned by its median value (3.5 g/l). Stratiﬁed mortality analysis by sex, CVD
at the baseline examination, median values of A1C, diabetes duration, LDL
cholesterol, and HDL cholesterol have also been performed. The likelihood
ratio test was used to assess the statistical signiﬁcance of examined variables
in nested models. We also carried out analyses that included terms for the
interaction between CRP and sex, A1C, BMI, waist, AER, and CVD. Tests for
nonproportional hazard using Schoenfeld residuals resulted in nonsigniﬁcant
ﬁndings in all analyses. The P value was two sided; a P value of 0.05 was
considered to indicate statistical signiﬁcance.
As statistical signiﬁcance does not imply either clinical signiﬁcance or
improvement in model performance, we also examined discrimination and
calibration of the model including CRP with respect to the model without CRP
in estimating individual mortality risk. In our analysis, discrimination is the
ability to separate diabetic subjects of the Casale Monferrato cohort who will
die and those who will survive during the 5-year follow-up period. This issue
is typically described by the concordance or C statistic, which is equivalent to
the area under the receiver-operating characteristic curve, and is calculated as
the fraction of pairs of subjects (one who has an event and one who does not)
for which the probability of the event is higher in the subject who has the
event. The C index can range from 0.5 (no predictive ability) to 1 (perfect
discrimination). In our analysis, the C statistic shows the proportion of pairs
for which the model assigns higher probability to the subject who has died
than to the subject who has survived. As the C statistic is a measure of
discrimination based on ranks, however, it is still debatable whether it is the
best way to assess the power of prediction for a given risk factor (16).
Therefore, we also provide as measure of model ﬁt the Bayes information
criterion, a likelihood-based measure that adds a penalty for model complex-
ity, with lower values indicating better ﬁt (25).
The second component of model performance is calibration. In our
analysis, it shows how close the probability of diabetic subjects dying as
predicted by the model including CRP is to the observed probability of dying
in this cohort. To assess this issue, we used the Grønnesby and Borgan
calibration test, which compares the number of events that are observed with
those that are expected on the basis of the estimation from the Cox models,
with four groups (26). Finally, to assess the impact of CRP values on clinical
reclassiﬁcation of mortality risk, we examined how many individuals would
be reclassiﬁed using the ﬁnal model with and without CRP. We categorized the
predicted probability of surviving into deciles (0–0.10, 0.10–0.20,…0.90–1.00)
to assess the number of people who were reclassiﬁed by CRP into different
categories of probability, separately among those who survived and those who
died. Analyses were performed with Stata software version 10.0.
RESULTS
Measurements of CRP values were available in 2,381 of
3,249 (73.3%) diabetic subjects of the population-based
Casale Monferrato Study. With respect to subjects who
were not recruited, those who were selected were younger
(67.6  10.4 vs. 73.2  12.9 years, P  0.0001), had lower
duration of the disease (10.7  7.9 vs. 14.0  9.4 years, P 
0.0001), and had lower A1C values (7.02  1.8 vs. 7.6  1.8,
P  0.0004) but similar systolic (145.7  16.4 vs. 145.9 
19.0 mmHg, P  0.93) and diastolic blood pressure (82.8 
8.2 vs. 82.6  8.0 mmHg, P  0.80). At the baseline
examination, most of diabetic subjects were elderly, 1,505
of 2,381 (63.2%) being 65 years at recruitment. A1C 7%
was obtained in 57.4% of the overall cohort (A1C inter-
quartile range 5.7–8.1).
The distribution of CRP was right skewed, with a
median value of 2.6 mg/dl (interquartile range 1.3–5.8). Sex
differences in CRP values were found, with signiﬁcantly
higher values (P  0.0001) in women than in men (3.1 mg/l
[1.4–6.9] vs. 2.2 mg/l [1.1–4.9]), even after adjustment for
age, BMI, waist, and blood pressure. CRP values were
positively correlated with BMI (r  0.30, P  0.0001),
waist circumference (r  0.27, P  0.0001), systolic blood
pressure (r  0.10, P  0.0001), diastolic blood pressure
(r  0.08, P  0.0006), plasma glucose (r  0.15, P 
0.0001), A1C (r  0.13, P  0.0001), total cholesterol (r 
0.10, P  0.0001), LDL cholesterol (r  0.10, P  0.0001),
apoB (r  0.16, P  0.0001), ﬁbrinogen (r  0.35, P 
0.0001), uric acid (r  0.15, P  0.0001), and AER (r 
0.10, P  0.0001) and negatively correlated with HDL
cholesterol (r 	 0.13, P  0.0001) and apoA1 (r 	 0.16,
P  0.0001).
As shown in Table 1, with respect to people with CRP
values in the lowest tertile, those with CRP values in the
highest tertile had similar age, duration of diabetes, smok-
ing habits, and glucose-lowering and statin treatments but
signiﬁcantly higher values of BMI, waist circumference,
blood pressure, and AER and plasma values of A1C, lipids,
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CVD.
During the 5-year follow-up period (median 5.4 years
[range 0.1–7.0]), 496 diabetic subjects died, of 11,716
person-years, giving an all-cause mortality rate per 1,000
person-years of 42.3 (95% CI 38.8–46.2). Table 2 shows
that with respect to people who survived, those who died
had higher values of CRP and other risk factors, such as
duration of diabetes, prevalence of hypertension, micro-
and macroalbuminuria, and CVD. Figure 1 shows the
Kaplan-Meier curves depicting the survival curves of
the cohort by CRP levels (log-rank test P  0.001).
Table 3 shows that HRs of all-cause mortality were
signiﬁcantly higher in people with CRP values in the
highest tertile compared with people with lower values
and that this excess was only slightly reduced after
multiple adjustment for age, sex, diabetes duration, hyper-
tension, LDL and HDL cholesterol, smoking, AER, A1C,
glucose-lowering treatment, CVD, waist circumference,
and treatment with statins. When this ﬁnal model was run
with clinically relevant CRP strata, we found that with
respect to CRP values 1 mg/l, HRs provided by CRP
values 1–3 mg/l and 3 mg/l were 1.03 (95% CI 0.72–1.47)
and 1.49 (1.00–2.05), respectively. Results were virtually
unmodiﬁed after further adjustment for ﬁbrinogen values;
indeed, in a fully adjusted model including both variables,
ﬁbrinogen values 3.5 g/l provided an HR of 1.30 (0.95–
1.77), whereas CRP 3 mg/l conferred an HR of 1.57
(1.15–2.15).
Cardiovascular mortality (ICD 390–459) accounted for
223 of 496 (45.0%) deaths, giving a mortality rate per 1,000
person-years of 19.0 (95% CI 16.7–21.7); 100 deaths oc-
curred among subjects with CRP 3.0 mg/l (rate 15.5 per
1,000 person-years [12.8–18.9]) and 123 among subjects
with CRP 3 mg/l (rate 23.3 per 100,000 person-years
[19.5–27.8]), giving an unadjusted HR of 1.53 (1.17–1.99)
and a fully adjusted HR of 1.44 (0.99–2.08) (Table 3).
In the analyses treating CRP as a continuous variable
after log transformation, fully adjusted models showed
22% (95% CI 10–36) increment of all-cause mortality and
17% (1–38) of cardiovascular mortality for each increment
of CRP (one natural logarithm  3.6 mg/l). In the ﬁnal
model, patterns of risk were similar in both sexes and in
strata deﬁned by median values of A1C, diabetes duration,
LDL and HDL cholesterol, presence or absence of central
obesity, and CVD at the baseline examination (Table 4).
AER 20 g/min and CRP 3 mg/l conferred similar
magnitude of the associations with both all-cause and
cardiovascular mortality, both of them providing higher
HRs than other risk factors, including lipids, blood pres-
sure, and glycemic control (Table 3). In normoalbuminuric
subjects, all-cause and cardiovascular HRs of CRP were
TABLE 1
Baseline characteristics of subjects with type 2 diabetes of the Casale Monferrato Study, by CRP values
CRP tertiles
P 1.6 mg/l 1.6–4.4 mg/l 4.4 mg/l
n 759 834 788
Men 434 (57.2) 422 (50.6) 328 (41.6) 0.0001
Age (years) 67.1  10.6 68.1  9.9 67.7  10.7 0.16
Duration of diabetes (years) 11.2  8.4 10.3  7.4 10.5  8.0 0.06
BMI (kg/m
2) 26.7  4.0 28.7  4.5 30.6  6.0 0.0001
Waist circumference (cm) 93.9  11.0 98.8  11.6 101.9  12.5 0.0001
Systolic blood pressure (mmHg) 143.2  15.9 146.7  15.9 147.1  17.0 0.0001
Diastolic blood pressure (mmHg) 81.8  7.9 82.2  8.1 83.4  8.5 0.0001
Hypertension 653 (86.3) 740 (89.1) 718 (91.1) 0.01
Glucose (mg/dl) 163.0  48.7 172.9  52.9 182.6  61.0 0.0001
A1C (%) 6.8  1.7 6.9  1.7 7.3  1.9 0.0001
Total cholesterol (mg/dl) 205.6  40.6 213.8  38.7 215.4  40.6 0.0001
LDL cholesterol (mg/dl) 123.0  35.5 128.7  31.9 130.9  35.0 0.0001
HDL cholesterol (mg/dl) 57.2  16.1 54.5  14.8 52.7  14.2 0.0001
Triglycerides (mg/dl) 113 (79–155) 134 (96–178) 141 (101–192) 0.0001
ApoA1 (mg/dl) 160.5  39.5 154.7  37.8 147.1  38.4 0.0001
ApoB (mg/dl) 96.1  26.0 103.5  25.9 106.7  27.4 0.0001
ApoB/apoA1 0.65  0.31 0.72  0.31 0.79  0.37 0.0001
Creatinine (mg/dl) 0.84 (0.70–0.97) 0.84 (0.71–0.98) 0.86 (0.69–1.02) 0.16
Fibrinogen (g/l) 353.5  66.5 371.8  68.9 413.1  96.2 0.0001
Uric acid (mg/dl) 5.22  1.44 5.57  1.55 6.08  2.53 0.0001
AER (g/min) 10.9 (4.0–22.6) 13.1 (4.6–27.7) 16.3 (4.9–40.7) 0.0001
20–200 137 (22.9) 169 (25.7) 184 (29.8) 0.0001
200 24 (4.0) 31 (4.7) 46 (7.5)
CVD 136 (17.9) 180 (21.6) 194 (24.6) 0.006
Smoking
Former smoker 243 (32.9) 236 (29.7) 221 (28.9) 0.28
Smoker 112 (15.2) 130 (16.3) 109 (14.2)
Glucose-lowering treatment
Diet 128 (17.0) 135 (16.4) 102 (13.1) 0.21
Oral drugs 549 (73.0) 605 (73.7) 585 (75.4)
Insulin 75 (10.0) 81 (9.9) 89 (11.5)
Statins 163 (21.5) 163 (19.5) 151 (19.2) 0.77
Data are means  SD, n (%), or geometric means (95% CI).
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When fully adjusted models were ﬁtted replacing CRP and
AER terms with an indicator variable with four categories
deﬁned by their joined effects (Table 5), we found that
with respect to the reference category (AER 20 g/min
and CRP 3 mg/l), HRs of both cardiovascular and all-
cause mortality were signiﬁcantly increased in all strata,
although no evidence of an effect modiﬁcation was found.
Indeed, when an interaction term was added to the ﬁnal
models of Table 2, no signiﬁcant interactions between
AER and CRP values were found (P  0.47 for all-cause
mortality and P  0.68 for cardiovascular mortality).
Moreover, no effect modiﬁcations of the relationship be-
tween CRP and mortality were found for A1C, BMI, waist
circumference, and sex.
We then examined the discrimination effect of adding
CRP measurement to classical cardiovascular risk factors
and AER, comparing models with and without CRP (Table
6). The C statistic pointed out a very limited advantage in
using CPR for both all-cause mortality (0.750 and 0.756
without and with CRP, respectively) and cardiovascular
mortality (0.799 and 0.802 without and with CRP, respec-
tively). The LR test comparing nested models with and
without CRP were highly signiﬁcant for all-cause mortality
but not for cardiovascular mortality (P  0.08). The Bayes
information criterion indicated quite similar values with
and without CRP. With regards to calibration, the P values
for the Grønnesby and Borgan statistics indicate good
calibration for both the models with and without CRP for
all-cause mortality and cardiovascular mortality (P  0.10
TABLE 2
Baseline characteristics of people with type 2 diabetes of the Casale Monferrato Study, by living status on 31 December 2006
Survived Deceased P
n 1,885 496
Men 922 (48.9) 262 (52.8) 0.12
Age (years) 65.9  10.2 74.1  8.5 0.0001
Duration of diabetes (years) 10.2  7.8 12.6  8.4 0.0001
CRP (mg/dl) 2.5 (1.2–5.3) 3.7 (1.6–9.1) 0.0001
1.6 642 (34.1) 117 (23.6) 0.0001
1.6–4.4 671 (35.6) 163 (32.8)
4.4 572 (30.3) 216 (43.6)
BMI (kg/m
2) 28.9  5.0 28.0  5.4 0.0009
Waist circumference (cm) 98.2  12.2 98.3  12.8 0.82
Systolic blood pressure (mmHg) 145.5  16.2 146.7  17.1 0.14
Diastolic blood pressure (mmHg) 83.0  8.2 82.3  8.4 0.10
Hypertension 1,653 (87.9) 458 (92.3) 0.005
Glucose (mg/dl) 171.5  53.5 178.3  60.0 0.014
A1C (%) 7.0  1.7 7.3  1.9 0.0003
Total cholesterol (mg/dl) 213.1  40.0 206.3  40.2 0.001
LDL cholesterol (mg/dl) 129.0  34.2 122.3  33.9 0.0002
HDL cholesterol (mg/dl) 54.7  14.8 55.0  16.6 0.70
Triglycerides (mg/dl) 129.6 (92–177) 127.7 (87–175) 0.57
ApoA1 (mg/dl) 154.9  38.8 150.7  39.1 0.03
ApoB (mg/dl) 102.8  26.3 100.0  28.3 0.04
ApoB/apoA1 0.72  0.33 0.72  0.34 0.99
Creatinine (mg/dl) 0.83 (0.69–0.97) 0.93 (0.73–1.11) 0.001
Fibrinogen (g/l) 372.1  68.5 406.9  110.4 0.0001
Uric acid (mg/dl) 5.52  1.73 6.04  2.51 0.0001
AER (g/min) 12.1 (4.2–25.5) 21.3 (6.4–49.3) 0.0001
20–200 377 (24.3) 113 (35.3)
200 73 (4.7) 28 (8.8)
CVD 353 (18.7) 157 (31.6) 0.0001
Smoking
Former smoker 534 (29.3) 166 (34.9) 0.03
Smoker 291 (16.0) 60 (12.6)
Glucose-lowering treatment
Diet 303 (71.0) 62 (12.7) 0.0001
Oral drugs 1,402 (75.4) 337 (68.9)
Insulin 155 (8.3) 90 (18.4)
Statins 379 (20.1) 98 (19.8) 0.98
Data are means  SD, n (%), or geometric means (95% CI).
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FIG. 1. Kaplan-Meier curves depicting the survival curves of the cohort
by CRP levels (dotted line CRP <3 mg/l, solid line >3 mg/ml). Log-rank
test P < 0.001.
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deciles of estimated probability of survival according to
models with and without CRP showed that among those
who survived, 39 people shifted upward and 90 shifted
downward by 1 decile of the surviving probability distri-
bution after inclusion of CRP in multivariate model; re-
TABLE 3
HRs (95% CI) of 5-year mortality in people with type 2 diabetes of the Casale Monferrato Study
All-cause mortality Cardiovascular mortality
Model 1 Model 2 Model 3 Model 1 Model 2 Model 3
CRP tertiles (mg/dl)
1.6 1.00 1.00 1.00 1.00 1.00 1.00
1.6–4.4 1.27 (1.00–1.62) 1.27 (0.98–1.64) 1.35 (0.98–1.87) 1.18 (0.82–1.68) 1.07 (0.73–1.56) 1.22 (0.74–2.00)
4.4 1.99 (1.58–2.49) 1.81 (1.41–2.32) 1.65 (1.20–2.28) 1.94 (1.39–2.71) 1.62 (1.13–2.33) 1.76 (1.09–2.82)
P for trend 0.0001 0.0001 0.0001 0.0001 0.006 0.015
CRP (mg/l)
3 mg/l 1.00 1.00 1.00 1.00 1.00 1.00
3 mg/l 1.64 (1.37–1.96) 1.49 (1.22–1.82) 1.51 (1.18–1.92) 1.53 (1.17–1.99) 1.32 (0.99–1.77) 1.44 (0.99–2.08)
AER
20 g/min 1.00 1.00
20 g/min 1.47 (1.15–1.87) 1.47 (1.01–2.14)
Hypertension 1.02 (0.64–1.63) 0.69 (0.36–1.34)
LDL cholesterol (1 SD) 0.89 (0.79–1.01) 1.07 (0.89–1.28)
HDL cholesterol (1 SD) 0.99 (0.88–1.13) 0.92 (0.76–1.12)
A1C (1 SD) 1.10 (0.97–1.26) 1.19 (0.97–1.44)
CVD 1.70 (1.31–2.22) 2.56 (1.74–3.76)
Antidiabetes treatment
Diet 1.00 1.00
Oral drugs 1.09 (0.76–1.57) 1.24 (0.68–2.24)
Insulin 1.81 (1.12–2.94) 2.29 (1.08–4.84)
Smoking
Never 1.00 1.00
Former smoker 1.34 (0.96–1.86) 1.24 (0.74–2.06)
Current smoker 1.42 (0.94–2.15) 0.74 (0.33–1.65)
Central obesity 0.87 (0.67–1.12) 0.92 (0.62–1.37)
Statins 1.02 (0.75–1.37) 1.31 (0.86–1.99)
Model 1: adjusted for age, sex, diabetes duration. Model 2: model 1 adjustments plus hypertension, LDL and HDL cholesterol, A1C, smoking
status, CVD, diabetes treatment, waist circumference, and statins. Model 3: model 2 adjustments plus AER.
TABLE 4
HRs (95% CI) of 5-year mortality in people with type 2 diabetes of the Casale Monferrato Study
All-cause mortality Cardiovascular mortality
Number of
deaths
HR (95% CI) for
CRP 3.0 mg/l
Number of
deaths
HR (95% CI) for
CRP 3.0 mg/l
Men 262 1.41 (1.02–1.96) 105 1.61 (0.94–2.74)
Women 234 1.66 (1.14–2.41) 118 1.51 (0.88–2.57)
Subjects without CVD at baseline
All cohort 339 1.67 (1.24–2.24) 133 1.36 (0.83–2.24)
Men 171 1.55 (1.03–2.32) 57 1.11 (0.52–2.37)
Women 168 1.71 (1.09–2.69) 76 1.62 (0.82–3.22)
A1C (%)
6.7 216 1.54 (1.08–2.19) 89 1.20 (0.67–2.14)
6.7 268 1.51 (1.07–2.11) 128 1.56 (0.94–2.57)
Diabetes duration (years)
8.7 202 1.60 (1.11–2.32) 76 1.29 (0.70–2.40)
8.7 291 1.48 (1.06–2.06) 144 1.54 (0.94–2.51)
LDL cholesterol (mg/dl)
126 265 1.38 (1.00–1.90) 95 1.41 (0.80–2.50)
128 199 1.72 (1.18–2.50) 110 1.49 (0.91–2.46)
HDL cholesterol (mg/dl)
51 237 1.55 (1.09–2.21) 109 1.50 (0.88–2.54)
51 242 1.52 (1.08–2.14) 106 1.45 (0.84–2.49)
Central obesity
No 241 1.40 (0.98–1.99) 102 1.46 (0.83–2.58)
Yes 255 1.71 (1.20–2.43) 121 1.48 (0.88–2.50)
HRs adjusted for age, sex, diabetes duration, LDL and HDL cholesterol, A1C, smoking status, CVD, AER, diabetes treatment, waist
circumference, and statins, apart from the stratiﬁcation variable.
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giving a nonsigniﬁcant net reclassiﬁcation improvement of
only 0.02.
DISCUSSION
This study was conducted to investigate the association
between plasma CRP values and 5-year mortality risk in
subjects with type 2 diabetes recruited as part of the
population-based Casale Monferrato Study, an ongoing
survey examining the epidemiology of diabetes over time
in Italy (19–21). We provide evidence that diabetic sub-
jects with CRP values 3 mg/l have 51% higher risk of
all-cause mortality and 44% higher risk of cardiovascular
mortality than diabetic subjects of similar age and sex,
independently of classical risk factors; the magnitude of
this association is similar to that provided by microalbu-
minuria, the main predictor of death in diabetic individu-
als. Second, increased risk of mortality is evident even in
people without CVD at baseline. Third, the role of CRP is
not confounded nor modiﬁed by AER. These ﬁndings
indicate that both markers of endothelial dysfunction
(AER) and inﬂammation (CRP) are useful in deﬁning
mortality risk over a 5-year period in diabetic subjects. In
our analyses, however, the C statistic failed to provide
evidence of increased discrimination of models including
CRP, and both models with and without CRP provide good
calibration. Moreover, from a clinical point of view, CRP
measurement allows the reclassiﬁcation of a very limited
proportion of patients on the basis of their 5-year proba-
bility of surviving; thus, the usefulness of this measure-
ment in addition to other risk factors commonly used in
clinical practice by diabetologists does not seem justiﬁed
at present. Indeed, the apparent advantage of CRP does
not translate into large improvement in 5-year mortality
risk prediction when other well-known risk factors are
utilized. Our ﬁndings are original, allowing us to point out
that previously obtained data on clinical usefulness of CRP
measurement in nondiabetic subjects do not extend to
high-risk diabetic subjects (2,3,15,27). Even in elderly
nondiabetic subjects recruited as part of the PROSPER
Trial, CRP values did not provide further additional pre-
diction of vascular events beyond established risk factors
in a 3-year follow-up period (18).
Our results on the association between CRP and mor-
tality are consistent with the few prospective studies
examining either cardiovascular events (4) or mortality in
diabetic subjects (10). The population-based study con-
ducted in Finland was limited to diabetic subjects aged
TABLE 5
HR (95% CI) of 5-year mortality in people with type 2 diabetes of the Casale Monferrato Study
All-cause mortality Cardiovascular mortality
HR (95% CI) HR (95% CI)
AER 20
g/min AER 20 g/min
AER 20
g/min AER 20 g/min
CRP 3 mg/l 1.00 1.48 (1.03–2.13) 1.00 1.74 (1.00–3.04)
CRP 3 mg/l 1.52 (1.11–2.09) 2.22 (1.60–3.09) 1.64 (1.00–2.69) 2.13 (1.26–3.61)
HRs adjusted for age, sex, diabetes duration, LDL and HDL cholesterol, A1C, smoking status, CVD, diabetes treatment, waist circumference,
and statins.
TABLE 6
Measures of discrimination and calibration in the Casale Monferrato Study, by selected variables
All-causes mortality Cardiovascular mortality
Discrimination
C statistic
Nonmodiﬁable risk factors (age, sex, and
diabetes duration) (model 1) 0.706 0.717
Established risk factors (model 2) 0.744 0.793
Established risk factors plus AER 0.750 0.799
Established risk factors plus AER and CRP 0.756 0.802
LR test
Established risk factors (model 2) LR  66, df  11, P  0.0001 LR  61.85, df  11, P  0.0001
Established risk factors plus AER LR  10.76, df  1, P  0.001 LR  4.69, df  1, P  0.03
Established risk factors plus AER and CRP LR  9.94, df  1, P  0.002 LR  3.03, df  1, P  0.08
Bayes information criterion
Nonmodiﬁable risk factors (age, sex, and
diabetes duration) (model 1) 4,021.24 1,693.40
Established risk factors 4,036.78 1,713.18
Established risk factors plus AER 4,033.45 1,715.90
Established risk factors plus AER and CRP 4,030.93 1,720.29
Calibration
Grønnesby and Borgan test
Nonmodiﬁable risk factors (age, sex, and diabetes
duration) (model 1) P  0.28 P  0.10
Established risk factors P  0.44 P  0.21
Established risk factors plus AER P  0.42 P  0.27
Established risk factors plus AER and CRP P  0.10 P  0.28
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subjects recruited as part of the Health Professional
Follow-Up Study was limited to men only (4). Moreover,
no study has examined the interrelationship between
microalbuminuria, the main predictor of death in people
with diabetes, and CRP (20). Our analyses pointed out that
even in normoalbuminuric subjects, CRP values 3 mg/l
are associated with a signiﬁcant 64% increased risk of
cardiovascular mortality, independently of classical risk
factors. As no multiplicative effect was found between
AER and CRP, it appears that both markers of endothelial
dysfunction and inﬂammation independently contribute to
increased mortality.
In our study, CRP was more strongly associated with
death than other risk factors, apart from AER, and this
association was found even in subjects with no evidence
of CVD at the baseline examination. Indeed, when CRP
was elevated, there was a signiﬁcant 51% increased risk of
all-cause mortality, which was virtually unaffected by
adjustment for traditional and new risk factors, including
AER and ﬁbrinogen. With regards to cardiovascular mor-
tality, there was a 44% signiﬁcantly higher adjusted risk,
which was marginally signiﬁcant, probably due to the
more limited number of person-years on which rates were
based. A population-based study conducted in nondiabetic
subjects aged 65 years with no evidence of baseline CVD
showed that CRP was associated with neither all-cause
nor cardiovascular mortality (17). This might suggest the
hypothesis of a different strength of the association be-
tween death and elevated CRP in diabetic compared with
nondiabetic subjects, probably reﬂecting the increased
activation of inﬂammation seen in these individuals.
In a previous report of the Casale Monferrato Study, we
found that ﬁbrinogen was signiﬁcantly and independently
associated with mortality (20). In this report, carried out in
a more recently recruited cohort with both CRP and
ﬁbrinogen measurements available in 60% of the cohort,
we found that the association between ﬁbrinogen and
death was mainly mediated through the effect of CRP. A
joint effect of A1C and CRP on cardiovascular event has
also been suggested in a clinic-based prospective study
including 454 people with advanced atherosclerosis, 40%
of whom had diabetes, the highest risk being evident in
people with CRP 4.4 mg/l and A1C 6.2% (28). In our
cohort, only 27 subjects had CRP values 4.4, and 17 of
them also had A1C 6.2%. Therefore, our study extends
previous observations to the large majority of diabetic
subjects in industrialized countries, who were mainly
elderly with a good level of glycemic control. CRP and A1C
were correlated, but neither confounding nor modiﬁcation
effect of A1C on the association between CRP and mortal-
ity risk was found over the range of examined values
(interquartile range 5.7–8.1%).
The strengths of the study are the recruitment of a large,
population-based cohort of diabetic subjects, the central-
ized measurement of risk factors and biomarkers, and the
high degree of completeness of baseline and follow-up
data. Several limitations of our analysis, however, deserve
comment. Subjects included in this report (73% of the
population-based cohort) were selected having a lower
cardiovascular risk proﬁle with respect to those who were
not recruited. It is likely, therefore, that the true associa-
tion between CRP and mortality is even higher than that
reported. Our results are based on an observational pro-
spective cohort. Although multivariate methods of analy-
ses were used to control for the effect of known
confounders of the relationship between CRP and mortal-
ity, we cannot rule out the possibility of residual or
undetected confounding on our results. This study also
used a single CRP measurement at baseline, and its
stability over time has not been shown deﬁnitively.
In conclusion, our population-based study indicates that
CRP value is independently associated with 5-year mortal-
ity risk in type 2 diabetic subjects, even in those who were
normoalbuminuric and in those without a previous
diagnosis of CVD. From a clinical point of view, how-
ever, the improvement in individual risk assessment was
only marginal.
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